Search

Your search keyword '"Mazurkov, Oleg Yu."' showing total 11 results
Start Over Author "Mazurkov, Oleg Yu."
11 results on '"Mazurkov, Oleg Yu."'

5. Roots of Rosa majalisHerrm. as a source of antioxidants and anti-influenza agents

Author

Karpova, Evgeniya A., Kostikova, Vera A., Khramova, Elena P., Shaldaeva, Tatiana M., Vasil’eva, Olga Yu., Mazurkova, Natalia A., Filippova, Ekaterina I., Mazurkov, Oleg Yu., and Makarevich, Elena V.

Abstract

Rosa majalisHerrm. (Rosaceae) is a shrub widespread throughout Eurasia. In West Siberia, it is cultivated as an ornamental plant and raw material for the manufacture of fruit multivitamin concentrates. Meanwhile, metabolites and biological activities of its roots are poorly studied. The aim of this investigation was to evaluate the potential of ethyl acetate (EtOAc), butanol (ButOH), aqueous ethanol (EtOH), and aqueous (H2O) extracts of R. majalisroots as sources of antioxidant and anti-influenza compounds. Spectrophotometry and HPLC were used for metabolite quantification. Antioxidant activities were determined via the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay. The antiviral activities were assessed as half-maximal inhibitory concentrations (IC50). The EtOAc extract manifested the highest concentrations of phenolic compounds (53.79 mg g−1of dry extract) and saponins (48.92 mg g−1). Total gallic acid was the main phenolic compound in all extracts (24.98–38.68 mg g−1). Catechin, free ellagic acid, and total ellagic acid had the highest levels in the EtOAc, H2O, and EtOH extracts, respectively (30.83, 22.38, and 34.95 mg g−1). The EtOAc extract showed the highest free-radical scavenging activity (2.31 trolox equivalents) and anti-influenza effects (IC5061.8 and 50.3 µg mL−1) against A/Aichi/2/68 (H3N2) and A/Chicken/05/2005 (H5N1), respectively. Our findings indicate good potential of these extracts for drug design against free-radical damage and influenza virus.

Published
2024
Full Text
View/download PDF

6. Safety and Pharmacokinetics of the Substance of the Anti-Smallpox Drug NIOCH-14 after Oral Administration to Laboratory Animals

Author

Shishkina, Larisa N., primary, Mazurkov, Oleg Yu., additional, Bormotov, Nikolai I., additional, Skarnovich, Maksim O., additional, Serova, Olga A., additional, Mazurkova, Natalia A., additional, Skarnovich, Maria A., additional, Chernonosov, Alexander A., additional, Selivanov, Boris A., additional, Tikhonov, Alexey Ya., additional, Gamaley, Svetlana G., additional, Shimina, Galina G., additional, Sysoyeva, Galina M., additional, Taranov, Oleg S., additional, Danilenko, Elena D., additional, Agafonov, Alexander P., additional, and Maksyutov, Rinat A., additional

Published
2023
Full Text
View/download PDF

9. New effective chemically synthesized anti-smallpox compound NIOCH-14

Author

Mazurkov, Oleg Yu., primary, Kabanov, Alexey S., additional, Shishkina, Larisa N., additional, Sergeev, Alexander A., additional, Skarnovich, Maksim O., additional, Bormotov, Nikolay I., additional, Skarnovich, Maria A., additional, Ovchinnikova, Alena S., additional, Titova, Ksenya A., additional, Galahova, Darya O., additional, Bulychev, Leonid E., additional, Sergeev, Artemiy A., additional, Taranov, Oleg S., additional, Selivanov, Boris A., additional, Tikhonov, Alexey Ya., additional, Zavjalov, Evgenii L., additional, Agafonov, Alexander P., additional, and Sergeev, Alexander N., additional

Published
2016
Full Text
View/download PDF

11. Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice.

Author

Skarnovich MA, Emelyanova AG, Petrova NV, Borshcheva AA, Gorbunov EA, Mazurkov OY, Skarnovich MO, Tarasov SA, Shishkina LN, and Epstein OI

Subjects
Animals, CD4 Antigens antagonists & inhibitors, CD4 Antigens immunology, Drug Administration Schedule, Drug Dosage Calculations, Female, Histamine immunology, Influenza A Virus, H3N2 Subtype growth & development, Influenza A Virus, H3N2 Subtype immunology, Interferon-gamma antagonists & inhibitors, Interferon-gamma immunology, Longevity immunology, Lung drug effects, Lung immunology, Lung virology, Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections mortality, Orthomyxoviridae Infections virology, Oseltamivir pharmacology, Survival Analysis, Treatment Outcome, Viral Load drug effects, Antibodies pharmacology, Antiviral Agents pharmacology, Immunologic Factors pharmacology, Influenza A Virus, H3N2 Subtype drug effects, Orthomyxoviridae Infections drug therapy
Abstract

Background: The influenza A virus accounts for serious annual viral upper respiratory tract infections. It is constantly able to modify its antigenic structure, thus evading host defence mechanisms. Moreover, currently available anti-influenza agents have a rather limited application, emphasizing the further need for new effective treatments. One of them is ergoferon, a drug containing combined polyclonal antibodies - anti-interferon gamma, anti-CD4 receptor and anti-histamine - in released-active form. The purpose of the study was to assess ergoferon antiviral efficacy in mice challenged with the A/Aichi/2/68 (H3N2) influenza virus., Methods: The virus was inoculated intranasally at a 90% lethal dose. Ergoferon was administered at 0.4 ml/day per os in a preventive and therapeutic regimen - daily for 5 days prior to and for 16 days after the challenge. The reference product, Tamiflu (oseltamivir), was used as a positive control treatment - at 20 mg/kg/day for 5 days after the challenge. Mice in the negative control group received distilled water which had been utilized for test sample preparation; untreated control animals received no treatment. Antiviral efficacy was assessed by an increase in survival rate, average life expectancy and virus titre reduction in the challenged mouse lungs., Results: Survival rate and average life expectancy values were increased significantly in groups treated with ergoferon and Tamiflu, as compared with controls. Lung virus titres were reduced in these groups as observed on days 2 and 4 post-inoculation., Conclusions: Ergoferon demonstrated antiviral activity by reducing the severity and duration of the major signs of induced influenza infection.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results